These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 3392332)
41. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease. Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166 [TBL] [Abstract][Full Text] [Related]
42. The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications. Waxman HL; Buxton AE; Sadowski LM; Josephson ME Circulation; 1983 Jan; 67(1):30-7. PubMed ID: 6847803 [TBL] [Abstract][Full Text] [Related]
44. The plasma catecholamine response to ventricular tachycardia induction and external countershock during electrophysiologic testing. Morady F; DiCarlo LA; Halter JB; de Buitleir M; Krol RB; Baerman JM J Am Coll Cardiol; 1986 Sep; 8(3):584-91. PubMed ID: 3745704 [TBL] [Abstract][Full Text] [Related]
45. The interplay between endogenous catecholamines and induced ventricular tachycardia during electrophysiologic testing. Morady F; Halter JB; DiCarlo LA; Baerman JM; de Buitleir M Am Heart J; 1987 Feb; 113(2 Pt 1):227-33. PubMed ID: 3812177 [TBL] [Abstract][Full Text] [Related]
46. Electrocardiographic signal-averaging during atrial pacing and effect of cycle length on the terminal QRS in patients with and without inducible ventricular tachycardia. Kremers MS; Black WH; Lange R; Wells PJ; Solo M Am J Cardiol; 1990 Nov; 66(15):1095-8. PubMed ID: 2220637 [TBL] [Abstract][Full Text] [Related]
47. Use-dependent electrophysiologic effects of amiodarone in coronary artery disease and inducible ventricular tachycardia. Chiamvimonvat N; Mitchell LB; Gillis AM; Wyse DG; Sheldon RS; Duff HJ Am J Cardiol; 1992 Sep; 70(6):598-604. PubMed ID: 1324598 [TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Connolly SJ; Kates RE; Lebsack CS; Echt DS; Mason JW; Winkle RA Am J Cardiol; 1983 Dec; 52(10):1208-13. PubMed ID: 6359849 [TBL] [Abstract][Full Text] [Related]
49. Effect of procainamide on induced ventricular tachycardia. Engel TR; del Gonzalez A; Meister SG; Franki WS Clin Pharmacol Ther; 1978 Sep; 24(3):274-82. PubMed ID: 688720 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of propafenone in preventing ventricular tachycardia: inverse correlation with rate-related prolongation of conduction time. Kus T; Dubuc M; Lambert C; Shenasa M J Am Coll Cardiol; 1990 Nov; 16(5):1229-37. PubMed ID: 2229772 [TBL] [Abstract][Full Text] [Related]
51. Immediate quantitation of antiarrhythmic drug effect by monophasic action potential recording in coronary artery disease. Platia EV; Weisfeldt ML; Franz MR Am J Cardiol; 1988 Jun; 61(15):1284-7. PubMed ID: 3376887 [TBL] [Abstract][Full Text] [Related]
52. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia. Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711 [TBL] [Abstract][Full Text] [Related]
53. Electrophysiologic and clinical factors influencing response to class IA antiarrhythmic agents in patients with inducible sustained monomorphic ventricular tachycardia. Gold RL; Haffajee CI; Alpert JS Am Heart J; 1986 Jul; 112(1):9-13. PubMed ID: 3728294 [TBL] [Abstract][Full Text] [Related]
54. Effects of quinidine on ventricular repolarization. Brugada J; Sassine A; Escande D; Masse C; Puech P Eur Heart J; 1987 Dec; 8(12):1340-5. PubMed ID: 3436332 [TBL] [Abstract][Full Text] [Related]
55. Atypical ventricular tachycardia as a manifestation of disopyramide toxicity. Meltzer RS; Robert EW; McMorrow M; Martin RP Am J Cardiol; 1978 Dec; 42(6):1049-53. PubMed ID: 727132 [TBL] [Abstract][Full Text] [Related]
56. Refractoriness as a determinant of tachycardia inducibility in the right ventricle. Somberg JC; Schwartz J Am Heart J; 1987 Aug; 114(2):311-4. PubMed ID: 3604887 [TBL] [Abstract][Full Text] [Related]
58. Procainamide, disopyramide and quinidine: discordant antiarrhythmic effects during crossover comparison in patients with inducible ventricular tachycardia. Wyse DG; Mitchell LB; Duff HJ J Am Coll Cardiol; 1987 Apr; 9(4):882-9. PubMed ID: 3558987 [TBL] [Abstract][Full Text] [Related]
59. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide: evidence for distinct mechanisms. Callans DJ; Marchlinski FE J Am Coll Cardiol; 1992 Jan; 19(1):111-7. PubMed ID: 1729321 [TBL] [Abstract][Full Text] [Related]
60. Ethmozine: electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias. Dorian P; Echt DS; Mead RH; Lee JT; Lebsack CS; Winkle RA Am Heart J; 1986 Aug; 112(2):327-33. PubMed ID: 3526852 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]